NCT06708455 2026-03-19
Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma
Rapa Therapeutics LLC
Phase 2 Not yet recruiting
Clinical Trials
15 trialsNCT07227870 2026-03-09
L19IL2/TNF in Patients With Basal Cell Carcinoma
Philogen S.p.A.
Phase 2 Not yet recruiting
NCT07455331 2026-03-06
LANCE
Jules Bordet Institute
Phase 2 Not yet recruiting
NCT07405086 2026-02-12
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
OHSU Knight Cancer Institute
Phase 2 Not yet recruiting
NCT07406724 2026-02-12
HS-IT101 Injection Versus Chemotherapy in the Treatment of Advanced Melanoma
Qingdao Sino-Cell Biomedicine Co., Ltd.
Phase 2 Not yet recruiting
NCT07387198 2026-02-04
NeoMatryx
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Not yet recruiting
NCT07340619 2026-01-14
EPIBREAST
UNICANCER
Phase 2 Not yet recruiting
NCT07040280 2025-06-27
Testing the Effect of Sulforaphane, a Compound Naturally Found in Cruciferous Vegetables, on Preventing Melanoma in Patients With a Prior History of Melanoma
Eastern Cooperative Oncology Group
Phase 2 Not yet recruiting
NCT04429308 2025-05-08
PDT vs Peels for Treatment of Actinic Keratoses
Northwestern University
Phase 2 Not yet recruiting
NCT06670300 2024-11-01
Clinical Observation on the Safety and Efficacy of Cardonilmab in the Treatment of Second-line and Above Advanced Melanoma and Advanced Renal Cancer
Henan Cancer Hospital
Phase 2 Not yet recruiting
NCT06500091 2024-07-15
TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Not yet recruiting
NCT06470880 2024-06-24
DyNAMIc
The Christie NHS Foundation Trust
Phase 2 Not yet recruiting
NCT06327698 2024-03-25
Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure
Hunan Cancer Hospital
Phase 2 Not yet recruiting
NCT06086288 2023-10-17
PANDORA
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Not yet recruiting
NCT02498756 2015-07-15
Cytokine-induced Killer Study for Patients With Stage II Melanoma
The First People's Hospital of Changzhou
Phase 2 Not yet recruiting